{
    "clinical_study": {
        "@rank": "149625", 
        "arm_group": [
            {
                "arm_group_label": "Bi-hormonal Bionic Pancreas", 
                "arm_group_type": "Experimental", 
                "description": "Bi-hormonal Bionic Pancreas"
            }, 
            {
                "arm_group_label": "Usual Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Usual Care"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will test the hypothesis that a wearable automated bionic pancreas system that\n      automatically delivers both insulin and glucagon can improved glycemic control vs. usual\n      care for young people with type 1 diabetes 12-20 in a diabetes camp environment."
        }, 
        "brief_title": "The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 12-20 years with type 1 diabetes for at least one year.\n\n          -  Diabetes managed using an insulin infusion pump and rapid- or very-rapid-acting\n             insulins including insulin aspart (NovoLog), insulin lispro (Humalog), and insulin\n             glulisine (Apidra) for at least three months prior to enrollment.\n\n          -  Otherwise healthy (mild chronic disease such as asthma will be allowed if well\n             controlled that do not require medications that result in exclusion).\n\n        Exclusion Criteria:\n\n          -  Unable to provide informed assent\n\n          -  Unable to comply with study procedures.\n\n          -  Current participation in another diabetes-related clinical trial other than one that\n             is primarily observational in nature.\n\n          -  Total daily dose (TDD) of insulin that is > 2 units/kg.\n\n          -  Pregnancy (positive urine HCG), plan to become pregnant in the immediate future, or\n             sexually active without use of contraception\n\n          -  Hypoglycemia unawareness (self-reported or legal guardian report of consistent lack\n             of hypoglycemia symptoms when BG is < 50 mg/dl)\n\n          -  End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).\n\n          -  History of prolonged QT or arrhythmia\n\n          -  History of congenital heart disease or current known cardiac disease\n\n          -  Acute illness (other than non-vomiting viral illness) or exacerbation of chronic\n             illness other than type 1 diabetes at the time of the study.\n\n          -  Seizure disorder or history of hypoglycemic seizures or coma in the last five years\n\n          -  Untreated or inadequately treated mental illness (indicators would include symptoms\n             such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the\n             last year), or treatment with second generation anti-psychotic medications, which are\n             known to affect glucose regulation.\n\n          -  Electrically powered implants (e.g. cochlear implants, neurostimulators) that might\n             be susceptible to radiofrequency interference.\n\n          -  Use non-insulin, injectable (e.g. exenatide, pramlintide) or oral (e.g.\n             thiazolidinediones, biguanides, sulfonylureas, meglitinides, dipeptidyl peptidase-4\n             inhibitors, acarbose)anti-diabetic medications.\n\n          -  History of adverse reaction to glucagon (including allergy) besides nausea and\n             vomiting.\n\n          -  Unwilling or unable to completely avoid acetaminophen during the usual care and\n             closed-loop BG control portions of the study.\n\n          -  History of eating disorder such as anorexia, bulimia, \"diabulemia\" or omission of\n             insulin to manipulate weight\n\n          -  History of intentional, inappropriate administration of insulin leading to severe\n             hypoglycemia requiring treatment\n\n          -  Any factors that, in the opinion of the principal investigator, would interfere with\n             the safe completion of the study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833988", 
            "org_study_id": "2013p000561"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bi-hormonal Bionic Pancreas", 
                "description": "Automated blood glucose control via a closed-loop bionic pancreas device.", 
                "intervention_name": "Bi-hormonal Bionic Pancreas", 
                "intervention_type": "Device", 
                "other_name": "Boston University Bionic Pancreas"
            }, 
            {
                "arm_group_label": "Usual Care", 
                "description": "Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.", 
                "intervention_name": "Usual Care", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pancreatin", 
                "Pancrelipase"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "bionic pancreas", 
            "artificial pancreas", 
            "insulin", 
            "glucagon", 
            "continuous glucose monitoring (CGM)", 
            "outpatient", 
            "insulin pump", 
            "pediatrics", 
            "children", 
            "camp", 
            "summer camp"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "link": {
            "description": "Information about this and related studies", 
            "url": "http://www.bionicpancreas.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Summer Camp Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population at the Clara Barton Diabetes Camps", 
        "other_outcome": [
            {
                "measure": "Mean absolute relative deviation (MARD) of CGMG vs. scheduled HemoCue BG measurements in closed-loop and usual care periods", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in mean insulin total daily dose", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Fraction of time bionic pancreas not functioning properly due to: system crash, communication problem (continuous glucose monitor), communication problem (pumps), pump malfunction, tubing occlusion, infusion set failure)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference of outcome measures on day 1 vs. remaining days (days 2-5) and on day 1-2 vs. on remaining days (days 3-5) for both closed-loop and usual care", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }
        ], 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Steven J Russell, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Difference in average blood glucose (BG) between closed-loop and open-loop periods as determined from all scheduled HemoCue measurements with mean evenly weighted across the daytime and nighttime hours.", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in the percentage of the above subset of BG values less than 70 mg/dl.", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833988"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Steven J. Russell, MD, PhD", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Difference between closed-loop and open-loop in average BG as determined from all HemoCue measurements taken during the day/nighttime including all extra measurements taken before meals, taken during exercise, and taken for hypoglycemia monitoring.", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in percentage of the above subset of BG values less than 70 mg/dl.", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in average BG as determined from the pre-meal, pre-snack, before bed, 12:00 AM, and 3:45 AM HemoCue measurements (nine measurements per day)", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in the percentage of the above subset of BG values between the closed-loop control and usual care periods less than 70 mg/dl.", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in percentage of subjects with mean BG < 154 mg/dl", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference in the percentage of study days with mean BG < 154 mg/dl over the duration of the closed-loop period vs. the usual care period", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in number of hypoglycemic events as determined from HemoCue measurements", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in fraction of time spent within glucose ranges (< 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, > 180 mg/dl, > 250 mg/dl)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in mean BG during exercise", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in number of hypoglycemic episodes and nadir BG during exercise", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in mean BG and likelihood of hypoglycemia on nights after a period of exercise > 30 minutes vs. nights after days without exercise", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference of outcome measures on day 1 vs. remaining days (days 2-5) and on day 1-2 vs. on remaining days (days 3-5) in closed-loop and usual care periods", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in mean continuous glucose monitoring glucose (CGMG)", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in number of  CGMG events < 70 mg/dl (episodes separated by < 15 minutes will be considered a single episode) and nadir for each", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in fraction of time spent within CGMG ranges (< 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, > 180 mg/dl, > 250 mg/dl)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in area over the curve and below 70 mg/dl (measure of total hypoglycemia exposure)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in area over the curve and below 50 mg/dl (measure of total hypoglycemia exposure)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in percentage of subjects with mean CGMG < 154 mg/dl", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in percentage of study days with mean CGMG < 154 mg/dl", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in mean CGMG in the four hour period following meals", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in mean CGMG during exercise", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in number of incidents of  hypoglycemia and nadir CGMG during exercise", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in standard deviation of CGMG values (glycemic variability)", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in standard deviation of CGMG values at night (11:00 PM to 7:00 AM)", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in average BG as determined from all HemoCue measurements taken during the daytime including all extra measurements taken before meals, taken during exercise, and taken for hypoglycemia monitoring.", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in average BG as determined from all HemoCue measurements taken during the nighttime including all extra measurements taken for hypoglycemia monitoring.", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in percentage of the above subset of BG values at night less than 70 mg/dl.", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in number of hypoglycemic events at night as determined from HemoCue measurements", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in fraction of time at night spent within glucose ranges (< 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, > 180 mg/dl, > 250 mg/dl)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in mean CGMG at night", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in number of  CGMG events < 70 mg/dl (episodes separated by < 15 minutes will be considered a single episode) and nadir for each during nighttime hours", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in fraction of time spent within CGMG ranges (< 70 mg/dl, 70-120 mg/dl, 70-180 mg/dl, > 180 mg/dl, > 250 mg/dl) at night", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in area over the curve and below 70 mg/dl (measure of total hypoglycemia exposure) at night", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in area over the curve and below 50 mg/dl (measure of total hypoglycemia exposure) at night", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in standard deviation of CGMG values (glycemic variability) at night", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in number of carbohydrate interventions for hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in number of carbohydrate interventions for hypoglycemia at night", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in total number of grams of carbohydrate taken for hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "measure": "Difference between closed-loop and open-loop in total number of grams of carbohydrate taken for hypoglycemia at night", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Boston University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}